The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2023 | Advances in non-covalent BTK inhibitors for CLL: BRUIN study update
Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, comments on recent advances with the use of non-covalent BTK inhibitors for the treatment of patients with chronic lymphocytic leukemia (CLL), highlighting long-term follow-up data from the Phase I/II BRUIN study (NCT03740529). This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
